Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Biopharmaceutical Practice Regulatory

Our Regulatory services are designed to help biopharmaceutical companies to solve complex regulatory challenges, as well as reduce risk and expedite the development process, by applying a premier level of expertise to every client engagement.

Service Lines Include:

5


Click the Tabs Below for Case Studies, White Papers, and Articles

Case Studies
Articles
Blog
  • Tradeoff Analysis and Valuation

    Situation: A preclinical precision medicine biotech company, looking to leverage their genome editing platform technology, was seeking support in narrowing

     

    Read this Case Study

  • Go-to-Market Strategy and Tactical Deployment Plan

    Situation: A privately held emerging biotech company, with an innovative cancer detection test, retained Kineticos to assist them in effectively

     

    Read this Case Study

  • Business Planning and Launch

    Situation: An emerging concierge patient healthcare services company was nearing launch and requested that Kineticos support the final stages of

     

    Read this Case Study

  • Functional Process Improvement

    Situation: A leading global contract research organization dissatisfied with their lab’s scientific affairs function retained Kineticos to conduct an operational

     

    Read this Case Study

  • Lab Integration Strategy

    Situation: A global bioanalytical lab specializing in large-molecule bioanalysis was experiencing challenges while integrating with their large, geographically distant partner.

     

    Read this Case Study

  • Central Lab Operational Excellence

    Situation: A global contract research organization was experiencing operational challenges within the central lab causing the business unit to perform

     

    Read this Case Study

  • A Primer on Immuno-Oncology: Part 2 – Targeted Redirection of T Cells

    In addition to anticancer vaccines, cytokines, and immune checkpoint inhibitors, bispecific T cell engagers (BiTE) antibody (Ab) constructs, and chimeric

     

    Read this Article

  • Why is a “D” degree required for MSLs? Does industry have it wrong?

    Written by Glen Martin, Senior Vice President, Kineticos First and foremost to my friends and colleagues with Doctorate degrees: these

     

    Read this Article

  • What to Expect in the Upcoming Biopharma CEO Confidence Index

    Written by Kevin Hampton, VP of Marketing, Kineticos The first of two 2017 editions of the BCCI was launched last

     

    Read this Article

  • When Dealing With Failure – Remember Your Purpose

    Written by Abe Maingi, Senior Analyst, Kineticos Let me share a personal example of dealing with failure. After I fulfill

     

    Read this Article

  • Boston, San Francisco,…Research Triangle Park, NC?

    Written by Mark Osterman, Senior Vice President, Kineticos Last week, my colleagues and I attended a great local event at

     

    Read this Article

  • Drug Pricing – Is More Transparency Better?

    Written by Myung Soo Kim, PhD, Research Analyst, Kineticos My colleague, Mark Osterman, recently wrote an article discussing the evolution

     

    Read this Article

  • How Metrics Can Help Identify and Solve Operational Challenges

    Article Preview As the sophistication of operational practices across life sciences increases; unfortunately, so do the difficulty and complexity of

     

    Read this Blog Post

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Driving Revenue and EBIDTA at CROs through Customer Loyalty

    Article Preview Determining customer satisfaction and loyalty is a difficult endeavor for most businesses. Traditional voice of customer surveys are

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Next Generation Sequencing: Using Technology to Develop Mutually-Beneficial Partnerships

    Article Preview Arup Laboratories announced it will begin offering next-generation sequencing (NGS) based high resolution Human Leukocyte Antigen (HLA) genotyping

     

    Read this Blog Post


Contact Us Today to Discover How We Can Elevate Your Business Our Strategy Consulting Services Are Designed to Enhance Your Value

Contact Us Today
Top